Are you Dr. Tolar?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 13 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 Howard Ave Ypb-3
Yale Univ School Of Medicine
New Haven, CT 06510Phone+1 203-785-4085- Is this information wrong?
Summary
- Dr. Martin Tolar, MD is a neurologist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut and Massachusetts.
Education & Training
Boston University Medical CenterResidency, Neurology, 1998 - 2001
Charles University in Prague Faculty of MedicineClass of 1991
Certifications & Licensure
MA State Medical License 1999 - 2024
CT State Medical License 2002 - 2007
Publications & Presentations
PubMed
- 10 citationsAPOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline.Susan Abushakra, Anton P. Porsteinsson, Marwan N. Sabbagh, Luc Bracoud, Joël Schaerer, Aidan Power, John Hey, David Scott, Joyce Suhy, Martin Tolar> ;Alzheimer's & Dementia. 2020 Jan 1
- 1 citationsCorrection to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Hu...John A Hey, Petr Kocis, Jakub Hort, Susan Abushakra, Aidan Power, Martin Vyhnálek, Jeremy Y Yu, Martin Tolar> ;CNS Drugs. 2018 Dec 1
- 16 citationsDiscovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.John A Hey, Petr Kocis, Jakub Hort, Susan Abushakra, Aidan Power, Martin Vyhnálek, Jeremy Y Yu, Martin Tolar> ;CNS Drugs. 2018 Sep 1
- Join now to see all
Press Mentions
Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease ConferenceNovember 22nd, 2022- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s DiseaseSeptember 20th, 2022
- Alzheon Appoints Glenn Pauly as Head of CommercialSeptember 20th, 2022
- Join now to see all
